pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
TARGET
save

JAK

Janus kinase family; autoimmune and MPN target.

also known as: jak1, jak2, jak3, janus kinase

🐶 often sniffed alongside

top 7
  • tag510(k) Clearance43 co-mentions · 43 sources
  • tagAdCom43 co-mentions · 43 sources
  • tagOncology3 co-mentions · 3 sources
  • tagPulmonology3 co-mentions · 3 sources
  • tagNSCLC2 co-mentions · 2 sources
  • tagPain1 co-mentions · 1 sources
  • companyDuke University1 co-mentions · 1 sources
drugs
0
catalysts
0
news
129
companies
0

Top drugs

no drugs tagged with this interest yet

🐶 Top companies

no companies tagged with this interest yet

Recent catalysts

no catalysts tagged with this interest yet

Recent news

view all →
  • Lilly adds to buyout streak with $1.5B purchase of startup Calytrix↗
    biopharma dive · 3d ago
  • Lilly secures another myelofibrosis option via $1.5B deal for JPM-founded Calytrix↗
    fiercebiotech · 3d ago
  • Aclaris drops TSLP program from pipeline after flunking phase 2 eczema test↗
    fiercebiotech · 3d ago
  • Evommune inks molecular glue deal worth $1.1B biobucks to fill pipeline gap↗
    biospace · 14d ago
  • Alethio raises $90M to target rare blood cancers↗
    biopharma dive · 14d ago
  • Evommune signs $1B deal with China’s Hinova to enter same molecular glue niche as Novartis↗
    fiercebiotech · 14d ago
  • Geron’s Rytelo stumbles in phase 3 as Novartis gears up for post-JAK inhibitor blood cancer bid↗
    fiercebiotech · 22d ago
  • ESMO: Why Incyte sees itself ‘neck and neck’ with RevMed in KRAS G12D pancreatic cancer race↗
    fiercebiotech · 25d ago
Data sources
openFDA · ClinicalTrials.gov · pharmadog Linker
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?